the Haute Autorité de santé specifies the vaccination strategy for the first vaccines and children

The HAS proposed vaccination of children exposed to the virus may be considered on a case-by-case basis, especially for “the most vulnerable and immunocompromised”.

Article redigé par



Lecture time: 1 min.

New guidelines for monkeypox cases. The High Health Authority (HAS) recommended that on Monday, June 20, a single dose of vaccine be given to people at risk and vaccinated against smallpox before 1980, except for immunocompromised people. In addition, she proposed that vaccination of children exposed to the virus and likely to develop a severe form of the disease can be considered and evaluated on a case-by-case basis.

In May, the HAS recommended vaccinating adults with high-risk contact with monkeypox. It was then seized by the Ministry of Health to clarify the vaccination strategy to work on a confirmed case of smallpox for two groups of the population: primii vaccinați, ie people vaccinated in their childhood against smallpox, and children.

The High Authority therefore recommended the administration of a single dose of Imvanex (Bavarian Nordic) vaccine to those at risk who had received a smallpox vaccine with a first-generation vaccine before 1980, according to its opinion published on Monday. In this particular case, where people at risk are immunocompromised, previous vaccination with another smallpox vaccine does not change the pattern originally recommended for this population, which is three doses of Imvanex.

For children and adolescents, several studies on other vaccines using the same platform as Imvanex, at higher doses, have shown good tolerance in children over 4 months, HAS said. But the Imvanex vaccine is currently only allowed in adults. That is why the High Authority has advocated for reactive vaccination of children at risk “May be considered to protect exposed children and the potential for developing severe forms of the disease, especially the most vulnerable and immunocompromised”.

However, in the absence of clinical data on the safety of third-generation vaccines, HAS predicted vaccination of persons under 18 years of age. “Considered on a case-by-case basis by specialists alone and after a strict assessment of the benefits and risks for the minor concerned”.

Leave a Comment